Insider trading

Period: 120 months Stock: MGNX + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

78 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

78 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

78 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

78 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
78 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
78 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

78 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
19 Aug 2026
Peters Jeffrey Stuart Senior VP, GC, and Secretary
Sold on a plan
$129.09K 31,105 at 4.15
100%
Sold half or more
20 Aug 2025
HEIDEN WILLIAM K Director
Bought
$73.76K 49,500 at 1.49
80.5%
+80% of stake
19 Aug 2025
HEIDEN WILLIAM K Director
Bought
$76.76K 50,500 at 1.52
459%
First buy on file
15 Feb 2025
Smith Beth Ann VP, Controller & Treasurer
Sold at will
$1.08K 423 at 2.56
4.2%
Not planned
4 Apr 2024
Peters Jeffrey Stuart Senior VP and General Counsel
Sold on a plan 5×
$799.15K 51,395 at 15.55
100%
Sold half or more
6 Mar 2024
Peters Jeffrey Stuart Senior VP and General Counsel
Sold on a plan
$421.94K 19,625 at 21.50
68.8%
Sold half or more
4 Mar 2024
Risser Eric Blasius Chief Operating Officer
Sold on a plan 2×
$813.50K 41,159 at 19.76
51.4%
Sold half or more
4 Mar 2024
Karrels James SVP, CFO and Secretary
Sold on a plan
$615.00K 30,000 at 20.50
14.9%
Planned (10b5-1)
4 Mar 2024
Spitznagel Thomas Sr VP, Technical Ops
Sold on a plan
$200.00K 10,000 at 20.00
54.6%
Sold half or more
26 Feb 2024
Peters Jeffrey Stuart Senior VP and General Counsel
Sold on a plan
$277.66K 16,124 at 17.22
64.4%
Sold half or more
7 Feb 2024
Bonvini Ezio Sr VP, Research & CSO
Sold on a plan
$60.01K 3,334 at 18.00
4.5%
Planned (10b5-1)
5 Feb 2024
Peters Jeffrey Stuart Senior VP and General Counsel
Sold on a plan 2×
$1.26M 76,251 at 16.50
100%
Sold half or more
1 Feb 2024
Bonvini Ezio Sr VP, Research & CSO
Sold on a plan
$199.74K 13,316 at 15.00
15.1%
Planned (10b5-1)
19 Jan 2024
Bonvini Ezio Sr VP, Research & CSO
Sold on a plan
$159.79K 13,316 at 12.00
13.1%
Planned (10b5-1)
20 Dec 2023
Bonvini Ezio Sr VP, Research & CSO
Sold on a plan
$190.31K 18,880 at 10.08
15.7%
Planned (10b5-1)
2 Oct 2023
BIOTECH TARGET N V 10% owner
Bought
$669.59K 150,000 at 4.46
1.5%
7 Sep 2023
BIOTECH TARGET N V 10% owner
Bought
$1.05M 200,000 at 5.26
2.1%
30 Aug 2023
HURWITZ EDWARD Director
Bought
$73.65K 15,000 at 4.91
83.0%
First buy on file
10 Mar 2023
Peters Jeffrey Stuart Senior VP and General Counsel
Sold, plan not stated
$32.39K 5,372 at 6.03
100%
Sold half or more
14 Feb 2023
BIOTECH TARGET N V 10% owner
Bought
$2.53M 500,000 at 5.07
5.5%
19 Jan 2023
BIOTECH TARGET N V 10% owner
Bought
$794.93K 150,000 at 5.30
1.7%
27 Dec 2022
BIOTECH TARGET N V 10% owner
Bought
$1.12M 200,000 at 5.61
2.3%
23 Dec 2022
BIOTECH TARGET N V 10% owner
Bought
$1.18M 200,000 at 5.88
2.3%
22 Nov 2022
BIOTECH TARGET N V 10% owner
Bought
$1.79M 300,000 at 5.96
3.6%
24 Oct 2022
BIOTECH TARGET N V 10% owner
Bought
$1.09M 250,000 at 4.36
3.1%
21 Oct 2022
BIOTECH TARGET N V 10% owner
Bought
$1.16M 250,000 at 4.63
3.2%
20 Oct 2022
BIOTECH TARGET N V 10% owner
Bought
$1.14M 285,977 at 4.00
3.8%
19 Oct 2022
BIOTECH TARGET N V 10% owner
Bought
$623.92K 168,422 at 3.70
2.3%
15 Jun 2022
Karrels James SVP, CFO and Secretary
Bought
$98.80K 40,000 at 2.47
26.4%
First buy on file
19 Nov 2021
BIOTECH TARGET N V 10% owner
Bought
$3.70M 200,000 at 18.50
2.8%
29 Sep 2021
BIOTECH TARGET N V 10% owner
Bought
$2.05M 100,000 at 20.47
1.4%
28 Sep 2021
BIOTECH TARGET N V 10% owner
Bought
$2.06M 100,000 at 20.64
1.5%
17 Sep 2021
BIOTECH TARGET N V 10% owner
Bought
$3.99M 200,000 at 19.93
3.0%
16 Sep 2021
BIOTECH TARGET N V 10% owner
Bought
$8.38M 400,000 at 20.94
6.4%
Largest buy in 3 yrs
16 Jul 2021
Spitznagel Thomas Sr VP, BPD & Manufacturing
Sold, plan not stated
$125.05K 5,000 at 25.01
100%
Sold half or more
21 Jun 2021
BIOTECH TARGET N V 10% owner
Bought
$1.63M 75,000 at 21.74
1.2%
16 Jun 2021
BIOTECH TARGET N V 10% owner
Bought
$2.10M 100,000 at 21.04
1.6%
Largest buy in 3 yrs
15 Jun 2021
BIOTECH TARGET N V 10% owner
Bought
$1.54M 75,000 at 20.53
1.2%
First buy on file
15 Apr 2021
Spitznagel Thomas Sr VP, BPD & Manufacturing
Sold, plan not stated
$154.55K 5,000 at 30.91
100%
Sold half or more
22 Mar 2021
Karrels James SVP, CFO and Secretary
Sold, plan not stated
$495.00K 15,000 at 33.00
9.5%
22 Mar 2021
Bonvini Ezio Sr VP, Research & CSO
Sold, plan not stated
$125.34K 3,917 at 32.00
4.7%
8 Mar 2021
Peters Jeffrey Stuart General Counsel
Sold, plan not stated
$576.35K 21,749 at 26.50
100%
Sold half or more
29 Dec 2020
Risser Eric Blasius Sr VP & Chief Business Officer
Sold, plan not stated
$12.05K 500 at 24.10
1.1%
30 Nov 2020
Risser Eric Blasius Sr VP & Chief Business Officer
Sold, plan not stated
$11.68K 500 at 23.35
1.1%
28 Oct 2020
Risser Eric Blasius Sr VP & Chief Business Officer
Sold, plan not stated
$31.04K 1,500 at 20.69
3.3%
28 Sep 2020
Risser Eric Blasius Sr VP & Chief Business Officer
Sold, plan not stated
$12.67K 500 at 25.33
1.1%
18 Sep 2020
Bonvini Ezio Sr VP, Research & CSO
Sold, plan not stated
$586.85K 18,339 at 32.00
18.0%
17 Sep 2020
Bonvini Ezio Sr VP, Research & CSO
Sold, plan not stated
$1.33M 44,512 at 29.88
30.4%
9 Sep 2020
Sold, plan not stated 2×
$563.16K 20,773 at 27.11
100%
Sold half or more
26 Aug 2020
Risser Eric Blasius Sr VP & Chief Business Officer
Sold, plan not stated
$13.55K 500 at 27.10
1.1%
Showing 1–50 of 78. Page 1 of 2 Older →